Non-Hispanic White adults Insulin resistance factor / higher baseline HOMA-IR may accelerate early glycemic response CYP enzyme relevance / tirzepatide is not primarily CYP-metabolized, reducing pharmacogenomic dose variability GI side effects / nausea rates in SURMOUNT-1 were 24-33% across doses regardless of ethnicity Titration schedule / 4-week minimum at each dose level before escalation Key monitoring / fasting glucose, HbA1c, renal function, GI symptom burden PharmGKB status / no ethnicity-specific dosing annotations for tirzepatide as of 2026 How Tirzepatide Works and Why Ethnicity Enters the Conversation Tirzepatide is a dual GLP-1/GIP receptor agonist that reduces appetite, slows gastric emptying, and improves insulin sensitivity
Lexchin, J., & Mintzes, B
Your FTO gene variant (rs9939609) and MC4R receptor function influence how dramatically your metabolism shifts when GLP-1 therapy begins
While these risks are rare with medical weight loss Waxahachie, patients need to understand the risks and know how to respond to them if they occur
Due to the fact that ACTL6A did not regulate NRF2, we could reach the conclusion that ACTL6A functions in conjunction with NRF2 to regulate GCLC expression at the transcriptional level
To stay up to date with the latest Gallup News insights and updates, follow us on X